Search Results

You are looking at 11 - 20 of 71 items for :

  • "chemotherapy administration" x
  • All content x
Clear All
Full access

non-small-cell-lung . J Clin Oncol 2009 ; 27 : 591 – 598 . 2. Rasco DW Yan J Xie Y . Looking beyond Surveillance, Epidemiology, and End Results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a

Full access

Harold J. Burstein

make their way through the hallways, verify their chemotherapy administration using bar codes, confirm delivery of each drug dose with computerized prompts when treatments are due, and collect all the information in an elaborate electronic medical

Full access

Harold J. Burstein

pharmacy databases that track outpatient chemotherapy administration, investigators characterized use of 10 patent-protected, intravenous therapies as “on-label,” “off-label,” or, if off-label, conforming to the NCCN Drugs & Biologics Compendium (NCCN

Full access

Leila Family, Yanli Li, Lie Hong Chen, John H. Page, Zandra K. Klippel, and Chun Chao

first chemotherapy administration to the FN event, the beginning of the second chemotherapy cycle, termination of KSPC membership, death, or 28 days after the first chemotherapy administration, whichever came first. Patient characteristics included age

Full access

Annika M. Gustafson, Deborah J. Goldfrank, William A. Dunson, Daniel L. Mulkerin, Rebecca L. Caires, and Keith D. Eaton

harm cancer treatment can have on a fetus and the high possibility of unplanned pregnancy in WOCBPs, regular pregnancy screening and testing is recommended. 12 ASCO/Oncology Nursing Society (ONS) Chemotherapy Administration Safety Standards 13 inform

Full access

Ruth McCorkle, Rebecca Kirch, Kim Thiboldeaux, Julie Taylor, and Mark Gorman

needs and integrate meeting these needs into the standard of care. The Alliance has also submitted comments to the ASCO/Oncology Nursing Society Standards for Safe Chemotherapy Administration to support relevant references to psychosocial care. The

Full access

Anne A. Eaton, Camelia S. Sima, and Katherine S. Panageas

neoadjuvant setting were not standard in this era. FDA approval and NCCN Guideline information is displayed in Figure 1 . Characterization of Chemotherapy Use We identified Medicare claims associated with intravenous chemotherapy administration after

Full access

Sally Yowell Barbour

administration, with some agents causing emesis within a few hours. Delayed CINV occurs more than 24 hours after chemotherapy administration, although with some agents it can start as soon as 16 hours after administration. Delayed CINV most commonly lasts up to 3

Full access

Jeffrey Crawford, James Armitage, Lodovico Balducci, Charles Bennett, Douglas W. Blayney, Spero R. Cataland, David C. Dale, George D. Demetri, Harry P. Erba, James Foran, Alison G. Freifeld, Marti Goemann, Mark L. Heaney, Sally Htoy, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Laura Boehnke Michaud, Sarah C. Miyata, Martin S. Tallman, Saroj Vadhan-Raj, Peter Westervelt, and Michael K. Wong

(glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin’s lymphoma: factors influencing chemotherapy administration. Groupe d’Etude des Lymphomes de l’Adulte . Leuk Lymphoma 1997 ; 25 : 289 – 300 . 5 Timmer

Full access

Julia C. Shih and Anthony J. Olszanski

Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards, including standards for pediatric oncology . Oncol Nurs Forum 2017;44:31–43. 11. Bennett AV , Jensen RE , Basch E . Electronic patient